How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trend in net sales and profits over the past four years.

Breakdown:
Concord Biotech's net sales have steadily increased from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. The company's total expenditure, excluding depreciation, also grew, reaching INR 693.76 crore in March 2025, up from INR 439.66 crore in March 2022. Operating profit, excluding other income, improved significantly from INR 273.27 crore in March 2022 to INR 506.33 crore in March 2025, while the overall operating profit (PBDIT) increased from INR 296.69 crore to INR 550.78 crore in the same period. Profit before tax followed a similar upward trajectory, climbing from INR 241.16 crore in March 2022 to INR 495.87 crore in March 2025, and the profit after tax also saw a rise from INR 178.57 crore to INR 372.96 crore. The earnings per share (EPS) increased from INR 16.72 in March 2022 to INR 35.53 in March 2025, indicating improved profitability per share. Overall, Concord Biotech has demonstrated strong financial performance with increasing revenues and profits over the years.